Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9BR61
UPID:
ACBD6_HUMAN
Alternative names:
-
Alternative UPACC:
Q9BR61
Background:
Acyl-CoA-binding domain-containing protein 6 plays a crucial role in cellular lipid metabolism by binding long-chain acyl-coenzyme A molecules. It exhibits a strong preference for unsaturated C18:1-CoA, demonstrating lower affinity for unsaturated C20:4-CoA, and very weak affinity for saturated C16:0-CoA, highlighting its selectivity in lipid binding.
Therapeutic significance:
Understanding the role of Acyl-CoA-binding domain-containing protein 6 could open doors to potential therapeutic strategies. Its involvement in lipid metabolism suggests its potential impact on metabolic disorders, offering a promising avenue for research into novel treatments.